Effectiveness of Further Endocrine Therapy in Metastatic Breast Cancer
Author Information
Author(s): Amit Agrawal, John FR Robertson, KL Cheung
Primary Institution: City Hospital, University of Nottingham
Hypothesis
Can further endocrine therapy provide clinical benefit to metastatic breast cancer patients who have developed resistance to previous treatments?
Conclusion
Further endocrine therapy can still provide clinical benefit and reasonable duration of response even after initial resistance.
Supporting Evidence
- 71.3% of patients achieved clinical benefit from the first line of therapy.
- Clinical benefit rates decreased with each subsequent line of therapy.
- 29.4% of patients with de novo resistance showed clinical benefit on second line therapy.
Takeaway
Even if some breast cancer treatments stop working, doctors can still try other hormone treatments that might help the patient.
Methodology
Data was collected from a prospectively updated database of metastatic breast cancer patients and analyzed using SPSS software.
Limitations
The study may not account for all variables affecting treatment response, and the sample size for some lines of therapy was small.
Participant Demographics
Patients were predominantly postmenopausal women with oestrogen receptor positive metastatic breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website